[Clinical evaluation of post-surgical bleeding after a sugammadex injection]

Area of Science:

• Anesthesiology
• Pharmacology
• Surgical Oncology

Background:

• Sugammadex reverses neuromuscular blockade by encapsulating rocuronium and vecuronium.
• Concerns exist regarding sugammadex's impact on hemostasis, with reported longer clotting times.
• Recommendations suggest caution with sugammadex in patients with coagulation disorders.

Purpose of the Study:

• To evaluate the clinical impact of sugammadex on postoperative bleeding.
• To analyze bleeding events in patients undergoing cancer surgery with sugammadex reversal.

Main Methods:

• Retrospective study of 193 patients undergoing laparotomy for cancer surgery.
• Patients were grouped based on sugammadex use (none, 2 mg/kg, or 4 mg/kg) for reversal.
• Postoperative bleeding was assessed via reoperations, drain volumes, and dressing observations.

Main Results:

• No reoperations for hemostasis were required across all groups.
• No significant differences in clinically evaluated postoperative bleeding were observed among the groups.
• Sugammadex at 2 and 4 mg/kg was not associated with increased bleeding in this high-risk cohort.

Conclusions:

• Sugammadex at 2 and 4 mg/kg is not linked to increased bleeding in high-risk surgical patients.
• Further prospective studies are recommended for higher sugammadex doses (4 and 16 mg/kg) and patients with pre-existing coagulation abnormalities.